These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7949042)

  • 1. [The effect of various human interleukin-2 preparations and lymphokine-activated killer cells on antibody production in mice in vivo and human immunoglobulins in vitro].
    Potapnev MP; Garbuzenko TS; Vozniuk AV; Ruksha EV; Shadrin OV; Bykovskaia SN
    Biull Eksp Biol Med; 1994 Aug; 118(8):171-3. PubMed ID: 7949042
    [No Abstract]   [Full Text] [Related]  

  • 2. [The preclinical assessment of the activity and pharmacological action of native human interleukin-2].
    Malakhova NV; Treshchalin ID; Iobadze MS; Abronina IF; Bykovskaia SN; Iushkov SF; Pereverzeva ER; Syrkin AB; Raushenbakh MO
    Patol Fiziol Eksp Ter; 1990; (2):32-4. PubMed ID: 2381746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytotoxicity of lymphokine-activated killer cells in conjunction with pingyangmycin to human tongue carcinoma (Tca8113) in vitro and vivo].
    Duan JG
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1993 Jul; 28(4):231-3. PubMed ID: 7513629
    [No Abstract]   [Full Text] [Related]  

  • 6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell alloreactivity in the rat: I. Potent in vivo recruitment of rat natural killer cells with an interleukin-2-producing cell line in intraperitoneal diffusion chambers.
    Løvik G; Vaage JT; Naper C; Rolstad B
    Transplant Proc; 1993 Oct; 25(5):2800-1. PubMed ID: 8212239
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
    Duan DS
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
    Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
    Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
    Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
    Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis.
    Johansson BR; Unger ML; Albertsson P; Casselbrant A; Nannmark U; Hokland M
    Nat Immun; 1996-1997; 15(2-3):87-97. PubMed ID: 9162267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
    Song YF; Zhao YN; Li J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preincubation of tumor cells with the anti-(MHC) class I antibody OX18 enhances tumor cell lysis by interleukin-2-activated NK cells.
    Smits KM; Kuppen PJ; Eggermont AM; Fleuren GJ
    Transplant Proc; 1993 Oct; 25(5):2806-7. PubMed ID: 8212242
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulation of monocytes by IL-2-activated killer cells.
    Djeu JY; Wei S; Blanchard DK
    Immunol Ser; 1994; 61():75-82. PubMed ID: 8011758
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses.
    Mastrangeli G; Corinti S; Butteroni C; Afferni C; Bonura A; Boirivant M; Colombo P; Di Felice G
    Int Arch Allergy Immunol; 2009; 150(2):133-43. PubMed ID: 19439979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.